Company intelligence / Profile preview

DecisionRx

Dover, Delaware, United States

Ownership: Private
Development stage: Other

Overview

DecisionRx’s MTO platform is commercially deployed and has demonstrated that 78% of patients receive clinically actionable guidance, with estimated per-patient savings of $1,200 (under 65) to $3,600 (Medicare); over 80% of tested patients find results helpful[1][3][4].

Therapeutic areas: Other
Modalities: Non-pharmacological therapyPharmacogenomics (precision guidance for medication—acts via analytics, not a drug developer)
Industry: Molecular Diagnostics

Partnerships

Benecard PBF (strategic partnership for personalized pharmacy benefits)[1][4]Imperium Health (partnership to enhance value-based care delivery with MTO)[3]

Beyond the preview

Go deeper on DecisionRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DecisionRx.

Explore the full profile